This was posted on one of the fb groups that I follow. An interesting read for a newbie like me, for some its probably old news, but interesting none the less.

Death and Dividends: The Tysabri Debacle
 
 
For the last three to four years neurologists have been talking about the coming of a much more effective drug for MS. That drug was first called Antegren and then Tysabri. The story of Tysabri illustrates ...

212 PML cases and 46 deaths in Tysabri MS patients as of March 1st 2012




Biogen Idec have released the latest figures for PML cases and deaths following Tysabri infusions for Multiple Sclerosis

As of March 1, 2012, there have been 212 PML cases, of which 122 have been in the European Economic Area (EEA), 80 in the US and 10 in rest of world (ROW). 46 of the 212 patients with PML have ...

I've been on Tysabri for over seven (7) years. I've had almost 100 infusions. I was part of the clinical trial beginning (for me) Aug 2002 and went through to open label in Dec 2004. I had two open label infusions when it was yanked due to PML deaths. The double blind on the study was broken to find out that I was on the drug during the study. I went back on Tysabri April ...

Hi
Does anyone know or have experience of taking ldn while on tysabri? Is it contraindicated?

thanks and regards
M

Since January 2012 (as of Febuary 1), there have been six more PML patients and two more deaths.
It means 207 confirmed cases of PML and 44 of them have died (21%). :evil:
There have been about 98.000 MS patients on natalizumab worldwide.

I don't personally have MS. But my fiance does. She's currently in the hospital right now. The doctors found 5 new lesions on her brain and right now it's affecting her eyes. She's been on Copaxone since Mid-August or early September of this year and has had 2 relapses since then. The doctors are wanting to put her on Tysabri now, because they think that Copaxone isn't working. Which, I'm not sure if I 100% ...

Abstract

Objective To explore cell subsets and molecules that changed specifically in patients with multiple sclerosis (MS) who had an optimal response to natalizumab. Natalizumab is a monoclonal antibody that inhibits the migration of activated immune cells to the central nervous system. It shows high efficacy in modifying the natural history of MS and induces freedom of disease activity in about 40% of treated patients with MS.

Design Prospective study of intrathecal immunoglobulin synthesis ...

Abstract

Natalizumab is a highly effective immunomodulator in the treatment of multiple sclerosis (MS).

Treatment with natalizumab has been associated with progressive multifocal leukoencephalopathy (PML), an infection of the central nervous system (CNS) caused by a pathogenic form of the normally benign JC virus (JCV).

We searched PubMed and used current data from the natalizumab global safety database to assess risk factors and quantify the risk of PML.... Read More - ...

ASCEND study to evaluate the effectiveness of Tysabri in secondary progressive MS



Biogen Idec today announced a global Phase 3b study, ASCEND, that is being conducted to evaluate the effectiveness of Tysabri as a treatment for secondary-progressive multiple sclerosis (SPMS). According to the National Multiple Sclerosis Society, approximately half of all people initially diagnosed with relapsing-remitting multiple sclerosis (RRMS) - the most common form of multiple sclerosis (MS) - will transition to SPMS within ...

Biogen Idec and Elan Corporation, plc announced that the U.S. Food and Drug Administration (FDA) has approved a product label change for Tysabri that will help enable individual benefit risk assessment for patients with multiple sclerosis (MS). The new label identifies anti-JCV antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal leukoencephalopathy (PML).

This marks the third risk factor identified to help physicians and people ...